Skip to main content
. 2023 Feb 13;12(3):595–604. doi: 10.21037/tcr-22-1616

Table 2. Intraoperative condition and pathological staging.

Variables Pre-EC (n=103) Post-EC (n=113) Statistical value P value
Operation time1 (h), median [IQR] 3 [3, 4] 3 [3, 4] –1.773 0.076
Blood loss1 (mL), median [IQR] 200 [150, 300] 200 [150, 300] –1.695 0.090
Removed lymph nodes1, median [IQR] 32 [19, 39] 28 [18, 36] –1.294 0.196
Pathology2, n (%) 0.001 0.977
   Adenocarcinoma 94 (91.26) 103 (91.15)
   Non-adenocarcinoma 9 (8.74) 10 (8.85)
Staging3, n (%) 0.288
   I 85 (82.52) 84 (74.34)
   II 10 (9.71) 11 (9.73)
   III 7 (6.80) 17 (15.04)
   IV 1 (0.97) 1 (0.88)
Grading3, n (%) 0.001
   G1 70 (67.96) 48 (42.48)
   G2 20 (19.42) 37 (32.74)
   G3 12 (11.65) 26 (23.01)
   G4 1 (0.97) 2 (1.77)
Muscular invasion2, n (%) 3.087 0.079
   None or <1/2 layers 72 (69.90) 66 (58.41)
   ≥1/2 layers 31 (30.10) 47 (41.59)
Vascular invasion3, n (%) 0.012
   None 101 (98.06) 101 (89.38)
   With 2 (1.94) 12 (10.62)
Cervical invasion2, n (%) 0.042 0.837
   None 94 (91.26) 104 (92.04)
   With 9 (8.74) 9 (7.96)
Affecting the uterine adnexa3, n (%) 0.293
   No 98 (95.15) 103 (91.15)
   Yes 5 (4.85) 10 (8.85)
Lymphatic metastasis3, n (%) 0.003
   No 102 (99.03) 101 (89.38)
   Yes 1 (0.97) 12 (10.62)
Para-uterine invasion3, n (%) 0.248
   No 103 (100.00) 110 (97.35)
   Yes 0 (0.00) 3 (2.65)
Tumor size2, n (%) 0.262 0.609
   Max diameter <3 cm 64 (62.14) 74 (65.49)
   Max diameter ≥3 cm 39 (37.86) 39 (35.51)

1, nonparametric U test; 2, chi-squared test; 3, Fisher exact test. IQR, interquartile range; n, number; EC, endometrial carcinoma.